Whalesbook
Generics Spark Price War, Market Segmentation
The arrival of generic Semaglutide has kicked off an aggressive price war. Monthly treatment costs have fallen dramatically, from ₹8,800-₹16,400 for the original drug to ₹1,290-₹8,000 for generics. Vials are the cheapest, costing ₹1,290 to ₹1,750 per month, with pen devices priced between ₹1,800 and ₹8,000. This sharp price drop is carving out distinct market segments. Alkem, Natco Pharma, Eris Lifesciences, and Glenmark Pharmaceuticals are aiming to disrupt the market with low prices. Zydus Lifesciences is targeting the mid-tier, while major companies like Sun Pharma and Dr Reddy's Laboratories are concentrating on the higher-end generic market.
Analysts Predict $1.5 Billion Market Boom
Analysts anticipate a market driven by volume, with the leading three to four companies set to capture substantial market share. Companies are also looking for ways to stand out, such as through patient support programs. A prime example is Dr Reddy's collaboration with Nestle for its SEMAKARE service. The market's overall size is expected to surge, potentially growing sixfold from its current ₹1,400 crore to about ₹8,300 crore, with potential to reach ₹28,500 crore in the long term. Goldman Sachs projects the Indian GLP-1 market could hit $1.5 billion by FY31, fueled by a significant increase in sales volume following generic availability.
Firms Target Market Share with New Strategies
CLSA favors Sun Pharma and Torrent Pharma, expecting them to capture larger market shares. Torrent Pharma has the added advantage of being an early mover with oral versions of the drug. Macquarie points to innovation and unique device approaches from companies like Zydus. The intense competition is likely to lead to more price changes and new product developments as different formats become available, defining the future of this growing treatment segment.